[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hydatidiform-mole\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hydatidiform-mole":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,72,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100346042","study-of-different-therapeutic-strategies-in-hydatidiform-mole-with-lung-nodule-100346042",false,"NCT03785574","Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule","Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule，A Prospective Multicentre Randomized Controlled Trial","Inclusion criteria\n\nEligible patients have to meet all of the following criteria:\n\n1. Pathologically confirmed HM.\n2. The lung nodules are detected by lung CT and metastatic lesions could not be excluded (before or after the suction dilation and curettage).\n3. The hCG level does not meet FIGO diagnostic criteria (2018) of GTN.\n4. The patients are willing to compliant with the study protocol and be followed up at regular intervals.\n5. The patients agree to sign an informed consent form.\n\nExclusion criteria\n\n1. The patients with a previous history of lung nodules.\n2. The imaging impression of lung nodules suggested definitely caused by other diseases, such as tuberculosis, pneumonia, etc.\n3. The patients have undergone prophylactic hysterectomy or chemotherapy.\n4. Pathologically confirmed gestational trophoblastic neoplasia before and at enrollment.\n5. Patients have immunosuppressive diseases or take immunosuppressants.\n6. Patients are participating in other clinical trials at same time.\n7. Patients were unable or unwilling to provide written informed consent.","FEMALE","60 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of present study is to provide clinical evidences for the appropriate management of molar pregnancy with lung nodule. The hydatidiform mole patients with lung nodule ≥1.0cm will be randomized into 2 groups: A. treated with chemotherapy immediately, B. follow up until hCG level met FIGO diagnostic criteria of GTN (B1) or hCG level declined to normal spontaneously (B2). Lung nodule \\\u003C1.0cm will directly treated as group C",[26,27],"Hydatidiform Mole","Gestational Trophoblastic Neoplasia",[29,30,31],"Pulmonary Nodule","Chemotherapy","Chorionic Gonadotrophin","RECRUITING","2026-03-13",{"date":35,"type":36},"2026-03-16","ACTUAL",{"date":38,"type":36},"2018-12-24",{"date":40,"type":20},"2030-09-01",{"name":42,"class":43},"Women's Hospital School Of Medicine Zhejiang University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":17,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100608528","a-multi-center-cohort-study-of-hydatidiform-mole-in-china-cn-hm-01-100608528","NCT07202728","A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)","Application and Promotion of the Whole-process Management and Precision Diagnosis and Treatment System for Hydatidiform Mole: a Multi-center Cohort Study in China (CN-HM-01)","CN-HM-01","Inclusion Criteria:\n\n1. Clinically or pathologically diagnosed as hydatidiform mole.\n2. Availability of complete medical records, including clinical and pathological data.\n3. No evidence of myometrial invasion or metastasis.\n4. Serum hCG levels normalized after uterine evacuation with at least 6 months of follow-up, OR diagnosed with postmolar gestational trophoblastic neoplasia (pGTN) during follow-up.\n5. No history of psychiatric disorders, serious infectious diseases, or immune system diseases (such as systemic lupus erythematosus, myasthenia gravis, HIV infection, etc.).\n6. Willing to participate in this study and sign the relevant informed consent form.\n\nExclusion Criteria:\n\n1. Missing clinical data.\n2. Loss to follow-up: Do not return to participating hospital for follow-up visits after uterine evacuation, or could not be contacted for subsequent monitoring of hCG changes.\n3. Concomitant malignancies or autoimmune deficiency disorders (e.g., systemic lupus erythematosus, myasthenia gravis, HIV infection, etc.).\n4. As determined by the investigator, the presence of medical, psychological, social, occupational, or other conditions that would violate the study protocol or impair the subject's ability to provide informed consent.","18 Years",{"count":55,"type":20},1489,"2 Years","OBSERVATIONAL","This observational study aims to establish a national cohort of patients with hydatidiform mole (molar pregnancy) to investigate its malignant transformation rate and malignant transformation mechanisms, with the goal of developing and promoting precision diagnosis and treatment models across China.",[26],[26,61],"Observational Study","2025-09-23",{"date":64,"type":36},"2025-10-02",{"date":66,"type":36},"2025-07-09",{"date":68,"type":20},"2030-08-30",{"name":70,"class":43},"Obstetrics & Gynecology Hospital of Fudan University",14,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100488267","a-cohort-study-of-hydatidiform-mole-100488267","NCT05637892","A Cohort Study of Hydatidiform Mole","A Multi-center Cohort Study of Hydatidiform Mole","Inclusion Criteria:\n\n1. Patients who are diagnosed with hydatidiform mole (including: complete hydatidiform mole\u002Fpartial hydatidiform mole; one of twins with hydatidiform mole; ectopic pregnancy hydatidiform mole; macroscopic or microscopic hydatidiform changes indicating early complete or partial hydatidiform mole can not be excluded; atypical placental site nodule) for the first time;\n2. Age 13-55 years old;\n3. Obtain informed consent and sign an informed consent form\n\nExclusion Criteria:\n\n1. Patients who are unable to cooperate with the investigation such as mental disorders or cognitive impairment\n2. No histopathology diagnosis;\n3. Patients with other malignancies","13 Years","55 Years",{"count":82,"type":20},800,"The purpose of this study is to construct a cohort for the hydatidiform mole.",[26],"NOT_YET_RECRUITING","2022-12-05",{"date":88,"type":36},"2022-12-08",{"date":90,"type":20},"2022-12-01",{"date":92,"type":20},"2027-06-01",{"name":42,"class":43},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":102,"targetDuration":104,"studyType":57,"phases":4,"briefSummary":105,"conditions":106,"keywords":110,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":44},"100277557","the-french-national-reference-centre-of-gtd-100277557","NCT02892877","The French National Reference Centre of GTD","The French National Reference Centre of Gestational Trophoblastic Disease","French GTDC","Inclusion Criteria:\n\n* Patients are eligible if they have a histologically proven trophoblastic disease, or a diagnosis of gestational trophoblastic neoplasia done on an abnormal evolution of hCG\n\nExclusion Criteria:\n\n* none",{"count":103,"type":20},25500,"18 Months","The French Gestational Trophoblastic Disease (GTD) centre has been set up and active by registering, monitoring and treating women with GTD since november 1999. The aim is to improve the management of trophoblastic disease in France.\n\nAbout 850 new cases are registered each year and 140 women treated, mostly with chemotherapy and surgery.\n\nThe center works as follow, based on a multidisciplinary approach. The policy is that patient remains followed by her local physician, but can be seen and treated in the Center at demand and that the registry is done on a voluntary basis.\n\nEach administrative french area has a local expert team (oncologist and gynaecologist) who is able to look after the patients with the help of the national reference center physicians based in Lyon.\n\n* Once a doctor discovers a molar pregnancy, he contacts the center, with the agreement of his patient, for an opinion, an advice or simply to report the case.\n* The center sends to the doctor the informed consent form to be signed by the patient, a registering form and information about pathology for patient and physician, and first guidelines based on initial pathology report.\n\nThe patient remains followed by her gynecologist, who stays her first interlocutor throughout the whole process and she goes to her local laboratory for hCG monitoring;\n\n* A letter is sent to the initial pathology laboratory that originally carried the diagnosis of molar pregnancy to require slide sending to the pathologist referral center (9 experts with a specific pathologist national network) that centrally review initial diagnosis.\n* In the mean time, the data manager collects weekly hCG values to establish a follow-up chart. The physician is regularly informed by mail of the hCG evolution.\n* The local physician is contacted in case of modification of the diagnosis by the pathologist expert. The center informs him about length and monitoring methodology.\n* Emails or letters are sent at each step of the management (at inclusion, at hCG negativation, and at the end of hCG follow-up).\n* In case of abnormal hCG evolution (raise, plateauing or positivity at 6 months,) or if a neoplasia is anatomopathologically diagnosed (choriocarcinoma, PSTT or ETT), physician is immediately contacted by phone or email by referent gynaecologist. A complete work up including pelvic US with Doppler, pelvic MRI, thoraco-abdominal CT-scan with chest radiography if pulmonary nodules are present and brain MRI, is planned to determine the adequate treatment.\n\nVery briefly, based on imaging results, FIGO stade and score are calculated to determine the risk. In case of low-risk, a monochemotherapy is settled, while a polychemotherapy is started in case of high-risk disease.\n\nThe investigators have developped specific expertise at key levels of diagnosis, management, follow-up, fertility preservation and treatment.\n\nAssignments :\n\n* Registration and monitoring post diagnosis of complete or partial molar pregnancy, choriocarcinoma,PSTT, ETT, atypical placental site nodules\n* Histopathological analysis and genetics services\n* Measurement of human chorionic gonadotrophin (hCG) isoforms\n* Complex gynaecological surgery",[107,108,26,109],"Neoplasm, Trophoblastic","Gestational Trophoblastic Disease","Hydatidiform Mole, Invasive",[111,112,113,114,115,116,117,118],"Complete Hydatidiform mole","Partial Hydatidiform mole","Invasive mole","Choriocarcinoma","Post-molar neoplasia","Placental Site Trophoblastic Tumor (PSTT)","Epithelioid Trophoblastic Tumor (ETT)","hCG follow-up","2016-09-02",{"date":121,"type":20},"2016-09-08",{"date":123,"type":4},"1999-11",{"date":125,"type":20},"2029-11",{"name":127,"class":43},"Hospices Civils de Lyon"]